ArticleReproductive medicine and biology
Micronized Vaginal Progesterone Dose and Serum Progesterone Thresholds Determine Reproductive Outcomes in Frozen-Thawed Embryo Transfer With Hormone Replacement Therapy.
Article in Reproductive medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical Appraisal of "Micronized Vaginal Progesterone Dose and Serum Progesterone Thresholds Determine Reproductive Outcomes in Frozen-Thawed Embryo Transfer With Hormone Replacement Therapy".Reproductive medicine and biologyArticle
- Authors' Response to the Commentary on "Micronized Vaginal Progesterone Dose and Serum Progesterone Thresholds Determine Reproductive Outcomes in Frozen-Thawed Embryo Transfer With Hormone Replacement Therapy".Reproductive medicine and biologyArticle
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the combined effects of micronized vaginal progesterone (P4) dose and achieved serum P4 levels on reproductive outcomes in hormone replacement therapy-frozen embryo transfer (HRT-FET) cycles by classifying patients according to both parameters. Methods: This retrospective cohort study analyzed 1137 single good-quality blastocyst transfers performed between 2017 and 2022. Patients received OneCrinone 90 mg/day, Lutinus 300 mg/day, or Luteum 800 mg/day. Serum P4 levels on the day of embryo transfer (ET) and assisted reproductive technology (ART) outcomes were compared, including dose-serum P4-based subgroup analyses. Receiver operating characteristic analysis was used to explore a serum P4 cutoff for clinical pregnancy. Results: Higher daily doses were associated with increased serum P4 levels and higher implantation, clinical pregnancy, and live birth rates. An exploratory serum P4 cutoff of 13.1 ng/mL on the day of ET was associated with clinical pregnancy, with significantly better outcomes observed in patients with P4 ≥ 13.1 ng/mL. Dose-serum P4-based subgroup analyses showed that both parameters jointly influenced ART outcomes. Conclusion: In HRT-FET cycles, achieving adequate micronized vaginal P4 dosage together with sufficient serum P4 levels on the ET day is associated with improved ART outcomes. Monitoring serum P4 may help support individualized luteal phase management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.